Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ALPMY OTCMKTS:MKKGY OTCMKTS:OPHLF NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPMYAstellas Pharma$14.21-1.5%$15.38$9.11▼$17.35$25.72B0.08163,362 shs123,627 shsMKKGYMerck KGaA$29.84+0.5%$26.22$23.73▼$31.00$19.28B0.97100,319 shs35,923 shsOPHLFOno Pharmaceutical$14.55$14.42$9.20▼$18.67$6.84B0.331 shs1,900 shsUTHRUnited Therapeutics$568.43+0.5%$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPMYAstellas Pharma0.00%-3.27%-8.20%-10.80%+49.74%MKKGYMerck KGaA0.00%+9.83%+14.55%-1.78%+12.39%OPHLFOno Pharmaceutical0.00%0.00%0.00%-10.46%+40.20%UTHRUnited Therapeutics0.00%-0.03%-0.77%+20.07%+83.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPMYAstellas Pharma$14.21-1.5%$15.38$9.11▼$17.35$25.72B0.08163,362 shs123,627 shsMKKGYMerck KGaA$29.84+0.5%$26.22$23.73▼$31.00$19.28B0.97100,319 shs35,923 shsOPHLFOno Pharmaceutical$14.55$14.42$9.20▼$18.67$6.84B0.331 shs1,900 shsUTHRUnited Therapeutics$568.43+0.5%$563.25$272.12▼$609.35$24.13B0.6415,129 shs281,045 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPMYAstellas Pharma0.00%-3.27%-8.20%-10.80%+49.74%MKKGYMerck KGaA0.00%+9.83%+14.55%-1.78%+12.39%OPHLFOno Pharmaceutical0.00%0.00%0.00%-10.46%+40.20%UTHRUnited Therapeutics0.00%-0.03%-0.77%+20.07%+83.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPMYAstellas Pharma 2.80Moderate BuyN/AN/AMKKGYMerck KGaA 2.00HoldN/AN/AOPHLFOno Pharmaceutical 2.00HoldN/AN/AUTHRUnited Therapeutics 2.85Moderate Buy$619.428.97% UpsideCurrent Analyst Ratings BreakdownLatest OPHLF, ALPMY, UTHR, and MKKGY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026UTHRUnited Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$516.005/7/2026UTHRUnited Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$575.00 ➝ $735.005/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$707.00 ➝ $701.004/24/2026ALPMYAstellas Pharma Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/17/2026OPHLFOno Pharmaceutical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/10/2026UTHRUnited Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$471.00 ➝ $519.004/10/2026UTHRUnited Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$700.004/9/2026UTHRUnited Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy3/31/2026UTHRUnited Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$600.00 ➝ $660.003/31/2026UTHRUnited Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$486.00 ➝ $575.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPMYAstellas Pharma$14.21B1.81$1.80 per share7.90$5.52 per share2.57MKKGYMerck KGaA$23.87B0.81$8.60 per share3.47$50.18 per share0.59OPHLFOno Pharmaceutical$3.43B2.00$1.08 per share13.50$11.07 per share1.31UTHRUnited Therapeutics$3.18B7.58$32.99 per share17.23$139.02 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPMYAstellas Pharma$1.94B$1.0713.2310.68N/A13.66%24.19%11.30%7/29/2026 (Estimated)MKKGYMerck KGaA$2.95B$2.2513.2614.852.6912.07%8.93%5.13%8/6/2026 (Estimated)OPHLFOno Pharmaceutical$330.31M$0.9914.7017.74N/A13.51%8.55%6.58%8/3/2026 (Estimated)UTHRUnited Therapeutics$1.33B$27.0920.9817.661.8440.62%19.24%17.25%7/29/2026 (Estimated)Latest OPHLF, ALPMY, UTHR, and MKKGY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026MKKGYMerck KGaA$0.45$0.59+$0.14$0.59$5.93 billion$6.03 billion5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 million4/27/2026Q4 2026ALPMYAstellas Pharma$0.1941$0.33+$0.1359$0.15$3.28 billion$3.38 billion3/5/2026Q4 2025MKKGYMerck KGaA$0.47$0.28-$0.19$0.28$6.20 billion$6.11 billion2/25/2026Q4 2025UTHRUnited Therapeutics$6.78$7.70+$0.92$7.70$814.80 million$790.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALPMYAstellas Pharma$0.342.39%N/A31.78%N/AMKKGYMerck KGaA$0.351.17%N/A15.56%N/AOPHLFOno PharmaceuticalN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPMYAstellas Pharma0.231.090.84MKKGYMerck KGaA0.371.460.96OPHLFOno Pharmaceutical0.103.022.56UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPMYAstellas PharmaN/AMKKGYMerck KGaA0.10%OPHLFOno PharmaceuticalN/AUTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipALPMYAstellas PharmaN/AMKKGYMerck KGaAN/AOPHLFOno PharmaceuticalN/AUTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALPMYAstellas Pharma14,7541.81 billionN/ANot OptionableMKKGYMerck KGaA62,461646.21 millionN/ANot OptionableOPHLFOno Pharmaceutical4,287469.91 millionN/ANot OptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableOPHLF, ALPMY, UTHR, and MKKGY HeadlinesRecent News About These CompaniesUnited Therapeutics (NASDAQ:UTHR) CFO Sells $5,641,100.00 in StockMay 23 at 7:50 AM | insidertrades.comUnited Therapeutics Corporation $UTHR Holdings Decreased by LSV Asset ManagementMay 23 at 6:39 AM | marketbeat.comMeiji Yasuda Asset Management Co Ltd. Grows Stock Position in United Therapeutics Corporation $UTHRMay 23 at 5:49 AM | marketbeat.comPaul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) StockMay 23 at 4:11 AM | americanbankingnews.comBanque Cantonale Vaudoise Acquires New Stake in United Therapeutics Corporation $UTHRMay 23 at 3:35 AM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CFO Sells 10,000 Shares of StockMay 22 at 7:12 PM | marketbeat.comUnited Therapeutics Explores Pig Heart Transplants And Space Labs As Valuation LagsMay 22 at 1:42 PM | finance.yahoo.comInsider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of StockMay 22 at 7:29 AM | insidertrades.comJ.P. Morgan Keeps Their Buy Rating on United Therapeutics (UTHR)May 21 at 7:16 PM | theglobeandmail.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of StockMay 20, 2026 | insidertrades.comQuant ratings on Renaissance Technologies' top holdings: UTHR, PLTR, AAPLMay 20, 2026 | seekingalpha.comUTHR holds as Tyvaso shows 33% lower worsening risk in rare lung scarring diseaseMay 20, 2026 | msn.comUnited Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 SharesMay 19, 2026 | marketbeat.comUnited Therapeutics Corporation (UTHR) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of StockMay 19, 2026 | americanbankingnews.comUnited Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026May 18, 2026 | businesswire.comHC Wainwright Issues Pessimistic Outlook for UTHR EarningsMay 18, 2026 | americanbankingnews.comHC Wainwright Has Negative Estimate for UTHR Q2 EarningsMay 18, 2026 | marketbeat.comUnited Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026May 17, 2026 | businesswire.comLeuthold Group LLC Buys 3,126 Shares of United Therapeutics Corporation $UTHRMay 17, 2026 | marketbeat.comUnited Therapeutics Corporation $UTHR Stock Position Decreased by Thrivent Financial for LutheransMay 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPHLF, ALPMY, UTHR, and MKKGY Company DescriptionsAstellas Pharma OTCMKTS:ALPMY$14.21 -0.22 (-1.52%) As of 05/22/2026 03:58 PM EasternAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Merck KGaA OTCMKTS:MKKGY$29.84 +0.15 (+0.51%) As of 05/22/2026 03:53 PM EasternMerck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.Ono Pharmaceutical OTCMKTS:OPHLF$14.55 0.00 (0.00%) As of 05/22/2026Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.United Therapeutics NASDAQ:UTHR$568.43 +2.56 (+0.45%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$568.09 -0.34 (-0.06%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
